Registry Study Shows Cancer Centers Following Guidelines for Stereotactic Body Radiation Therapy - - Tulsa, OK - News, Weather, Video and Sports - |

Registry Study Shows Cancer Centers Following Guidelines for Stereotactic Body Radiation Therapy

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE New Jersey CyberKnife

New Jersey CyberKnife physicians part of nationwide group analyzing value of RSSearch Registry

TOMS RIVER, N.J., July 8, 2014 /PRNewswire/ -- Physicians at New Jersey CyberKnife, a service of Community Medical Center, are part of a group of cancer specialists around the U.S. that have analyzed patient data collected through the RSSearch Registry. The group has confirmed cancer centers participating in the registry are following established guidelines for stereotactic body radiation therapy (SBRT).

The CyberKnife treatment room at New Jersey CyberKnife. More than 460 patients have been treated at the center since it opened in 2011 as part of the J. Phillip Citta Regional Cancer Center at Community Medical Center.

The study is one of the first attempts to evaluate the quality of data gathered by the registry, a project launched in 2006 to collect standardized data on the use of SBRT.

"The registry was created as a means to follow patients systematically so treatment outcomes and results could be compared appropriately to experiences around the country in academic and nonacademic centers," says Dr. David D'Ambrosio, medical director of New Jersey CyberKnife and one of several authors of the analysis. "The system collects data and categorizes it in terms of patient toxicity and outcomes in a rigid manner so it can be compared to other centers' data."

In their study, Dr. D'Ambrosio and other authors examined 464 men with prostate cancer who were treated with SBRT between 2006 and 2013 at a total of 33 U.S. cancer centers that take part in providing data for the RSSearch Registry.

The study found biochemical disease-free survival at two years was 100 percent for low-risk patients, 93 percent for intermediate-risk patients and 93 percent for high-risk patients. At three years, biochemical disease-free survival for each category was 100 percent, 84 percent and 67 percent, respectively.

The study's authors concluded that patient outcomes are favorable. Dr. D'Ambrosio acknowledges the median patient follow-up of 13 months was relatively short. But as the database matures, he says, analysis will become more robust for assessing toxicity and long-term outcomes.

New Jersey CyberKnife opened in 2011 and has treated more than 460 patients. Diseases most frequently treated include head and neck tumors, lung tumors and prostate cancer. In collaboration with the University of Pittsburgh, the center is currently managing a clinical trial to analyze SBRT for prostate cancer patients.

Part of the J. Phillip Citta Regional Cancer Center, New Jersey CyberKnife is located at 99 Route 37 West in Toms River, NJ. For more information, call (732) 557-3120.

CONTACT: Chris Trahan, Zehnder Communications, (225) 505-1900,

Photo -

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
News On 6
303 N. Boston Ave.
Tulsa, OK 74103
Oklahoma's Own is proud to provide Oklahomans with timely and relevant news and information, sharing the stories, pictures and loves of Oklahomans across our great state including Tulsa's Own and Green Country's Own.
All content © Copyright 2000 - 2014, WorldNow and KOTV. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.